Sugi Predict

Sugi Predict / Targets / HSD17B3

HSD17B3

17-beta-hydroxysteroid dehydrogenase type 3 · P37058 · HSD17B3 on Sugi Atlas →

37,361 patent compounds predicted against HSD17B3, 23,907 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL536846 SCHEMBL536846 1.00 13/20
SCHEMBL205186 SCHEMBL205186 0.73 12/20
SCHEMBL85753 SCHEMBL85753 0.61 12/20
SCHEMBL592465 SCHEMBL592465 0.79 11/20
SCHEMBL533173 SCHEMBL533173 0.70 10/20
SCHEMBL498081 SCHEMBL498081 0.48 10/20
SCHEMBL263980 SCHEMBL263980 0.69 9/20
SCHEMBL591144 SCHEMBL591144 0.56 9/20
Hymecromone Hymecromone (SCHEMBL24150) 1.00 8/20
SCHEMBL151228 SCHEMBL151228 1.00 8/20
SCHEMBL420677 SCHEMBL420677 1.00 8/20
Hymecromone Hymecromone (SCHEMBL31014) 0.96 8/20
SCHEMBL124008 SCHEMBL124008 0.80 8/20
SCHEMBL433486 SCHEMBL433486 0.73 8/20
Paroxypropione Paroxypropione (SCHEMBL440470) 0.68 8/20
SCHEMBL319591 SCHEMBL319591 0.67 8/20
SCHEMBL99460 SCHEMBL99460 0.66 8/20
SCHEMBL548940 SCHEMBL548940 0.64 8/20
SCHEMBL548578 SCHEMBL548578 0.62 8/20
SCHEMBL507985 SCHEMBL507985 0.62 8/20

Clinical trials — most relevant to HSD17B3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment PHASE4RECRUITING
Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study PHASE3UNKNOWN
Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS) PHASE3COMPLETED
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy PHASE3COMPLETED
Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy PHASE3COMPLETED
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia PHASE1/PHASE2COMPLETED
Androgen Reduction in Congenital Adrenal Hyperplasia PHASE2WITHDRAWN
Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma PHASE2UNKNOWN
AMG 386 and Abiraterone for Advanced Prostate Cancer PHASE2COMPLETED
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer PHASE2RECRUITING
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer PHASE2COMPLETED
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency PHASE1COMPLETED
Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency nanUNKNOWN
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole nanWITHDRAWN
Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers nanUNKNOWN
Final Height in Patients With CAH nanUNKNOWN
Linear Growth of Children With Congenital Adrenal Hyperplasia nanUNKNOWN
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
Mutation Analysis of 17α-Hydroxylase nanUNKNOWN
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency nanCOMPLETED
Effect of Surgical or Conservative Approach in Patients With Adrenal Incidentalomas nanUNKNOWN
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome nanCOMPLETED
Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological Changes nanNOT_YET_RECRUITING
Cortisol Regulation in Polycystic Ovary Syndrome (PCOS) nanCOMPLETED
Adrenocortical Functions in Women With Nonclassical 21-hydroxylase Deficiency. nanUNKNOWN
Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH nanCOMPLETED
Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS) nanCOMPLETED
Biomarkers in the Etiology of Idiopathic Intracranial Hypertension nanUNKNOWN
Adrenal Function in GHD Children nanCOMPLETED
Impact of 11-oxygenated Androgens on Metabolic Dysfunction of Women With Polycystic Ovary Syndrome nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a HSD17B3 binder may also engage these)

ProteinNameSimilarity
P70385 — 1.000 P70385 →
O54939 — 0.999 O54939 →
A5PJF6 — 0.995 A5PJF6 →
Q6QA32 — 0.993 Q6QA32 →
O17795 — 0.993 O17795 →
O70503 — 0.992 O70503 →
Q6P7R8 — 0.991 Q6P7R8 →
Q5R7K0 — 0.991 Q5R7K0 →
Q17704 — 0.991 Q17704 →
Q3SXM5 — 0.991 Q3SXM5 →
Q9STY7 — 0.991 Q9STY7 →
Q8N3Y7 — 0.991 Q8N3Y7 →
Q5ZJG8 — 0.991 Q5ZJG8 →
HSD17B12 Very-long-chain 3-oxoacyl-CoA reductase 0.991 landscape →
Q17703 — 0.990 Q17703 →
Q6QA33 — 0.989 Q6QA33 →
Q6P3L6 — 0.989 Q6P3L6 →
Q8BTX9 — 0.989 Q8BTX9 →
Q4V8B7 — 0.989 Q4V8B7 →
A5PJJ7 — 0.989 A5PJJ7 →
Q8VCR2 — 0.989 Q8VCR2 →
Q4JK73 — 0.988 Q4JK73 →
A8Q1U2 — 0.988 A8Q1U2 →
Q8AVY8 — 0.988 Q8AVY8 →
P0DKC6 — 0.988 P0DKC6 →
P0DKC5 — 0.988 P0DKC5 →
Q5NVG2 — 0.987 Q5NVG2 →
Q05A13 — 0.987 Q05A13 →
Q5E9H7 — 0.987 Q5E9H7 →
Q6QLL4 — 0.987 Q6QLL4 →